Skip to main content
Top
Published in: Journal of Gastroenterology 6/2007

01-06-2007 | Rapid Communication

Preliminary results of a Japanese nationwide survey of neuroendocrine gastrointestinal tumors

Authors: Tetsuhide Ito, Masao Tanaka, Hironobu Sasano, Yoshiyuki R. Osamura, Iwao Sasaki, Wataru Kimura, Koji Takano, Takao Obara, Miyuki Ishibashi, Kazuwa Nakao, Ryuichiro Doi, Akira Shimatsu, Toshirou Nishida, Izumi Komoto, Yukio Hirata, Masayuki Imamura, Ken Kawabe, Kazuhiko Nakamura, The Neuroendocrine Tumor Workshop of Japan

Published in: Journal of Gastroenterology | Issue 6/2007

Login to get access
Metadata
Title
Preliminary results of a Japanese nationwide survey of neuroendocrine gastrointestinal tumors
Authors
Tetsuhide Ito
Masao Tanaka
Hironobu Sasano
Yoshiyuki R. Osamura
Iwao Sasaki
Wataru Kimura
Koji Takano
Takao Obara
Miyuki Ishibashi
Kazuwa Nakao
Ryuichiro Doi
Akira Shimatsu
Toshirou Nishida
Izumi Komoto
Yukio Hirata
Masayuki Imamura
Ken Kawabe
Kazuhiko Nakamura
The Neuroendocrine Tumor Workshop of Japan
Publication date
01-06-2007
Publisher
Springer-Verlag
Published in
Journal of Gastroenterology / Issue 6/2007
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-007-2056-6

Other articles of this Issue 6/2007

Journal of Gastroenterology 6/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine